Maryland Mesothelioma Information

Maryland

While mesothelioma is a problem in all states, the specific incident rate for Maryland is / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in MD, recent MD mesothelioma-related court cases, mesothelioma specialists in MD and potential asbestos hotspots in Maryland.

[doptabs]
[doptab title=”Overview”]

Maryland Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Maryland

Maryland Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Maryland Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Maryland Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

[/doptab]
[doptab title=”Treatment and Research”]

Research

[dopaccordions]
[dopaccordion title=”Kremen, Jerome C. Light Probe For Treatment Of Malignant Mesothelioma Grant: 1R43CA080520-01A1″ icon=27 activeicon=28]

Abstract: Currently approved spherical and cylindrical probes for photodynamic therapy have gained acceptance and wide use because they can uniformly irradiate internal body structures, deliver all of their optical power to the tissue of those structures and are capable of accurate calibration of the delivered dose. They accomplish this only when introduced into similarily shaped structures but are less successful when applied to single-sided surfaces such as a chest wall or the skin or to irregularly shaped structures. This proposal describes a new probe design which is expected to maintain the desirable features of the presently approved probes during these unsuitable conditions. The new probe takes the form of an inflatable bladder placed in contact or close proximity to the tissue to be treated. The first order design and performance of several variations of the basic configuration are analyzed. Optimization via optical design programs is outlined. Proposed fabrication and testing of the probe are detailed. The new probe will be adapted to the promising new treatment of malignant mesothelioma. PROPOSED COMMERCIAL APPLICATION: The applications of this probe lie in treatment of large area malignacies such as the malignant mesothelioma procedure and basal cell carcinoma and treatment of residual diseased areas after removal of tumors. There are 25 centers in the United States that would need one or more probes for mesothelioma. The number of basal cell procedures will be much greater. 

Tags: Biomedical Equipment Development, Mesothelioma, Neoplasm /cancer Photoradiation Therapy, Optics Light Intensity, Mathematical Model

[/dopaccordion]
[dopaccordion title=”Testa, Joseph R. Cytogenetics Of Human Lung Cancer & Mesothelioma
Grant: 1R01CA045745-01″ icon=27 activeicon=28]

Abstract: The overall goal of this proposal is to expand the understanding of the patterns and implications of chromosome alterations in human lung cancer and mesothelioma. Karyologic investigations will be performed on a series of tumors from patients with lung cancer or mesothelioma, with emphasis on analyses of untreated primary tumors. In order to generate meaningful correlative data, this project proposes a multidisciplinary study involving experienced collaborative investigators in the areas of cell culture cytogenetics pathology and medical oncology. The cancer cytogeneticists and cell culture experts will work closely in order to foster, improvements in existing methodologies. Several cell culture methods (growth in conventional and tumor-type specific media, and use of extra cellular matrix) will be compared in order to identify the most appropriate method(s) for successful in vitro growth of lung tumors and mesotheliomas and to determine whether different assays select for phenotypically and cytogenetically different cell populations within a tumor. This project will also evaluate and improve methods for the short-term culture and cytogenetic harvesting of cells derived from these tumors in an effort to increase the success rate and quality of karyologic investigations, including more precise identification of rearrangements and breakpoints. The karyology of both short-and long-term cultures will be assessed to determine the extent of karyotypic evolution occurring in vitro. Using the most appropriate techniques for growth and cytogenetic harvesting, we will determine the pattern of cytogenetic changes in a series of tumors to greatly expand the data base which will be required to identify recurring chromosome abnormalities. These may have biological and clinical significance. These alterations will be correlated with tumor phenotype, stage, and subsequent behavior. The proposed studies will also establish the frequency and specificity of deletions of 3p in tumors from patients with small- cell lung carcinoma. Tumors positive for double minutes and homogeneously staining regions will be examined for amplication of known or previously uncharacterized oncogenes. A long-term objective of this proposal is to relate specific chromosome defects found in lung cancer and mesothelioma to changes in the function and regulation of genes at affected breakpoints. Cells stored during this project period will be important for these future biological studies (e.g., for isolation, identification, and expression of DNA sequences that may have a significant role in tumorigenesis). Another long-term objective is to find reliable diagnostic and prognostic indicators. As the data base increases in the future, it will be possible to recognize significant correlations between the karyotype and important clinical parameters, including response to therapy. 

Tags: Diagnostic Tests, Cytodiagnosis, Genetics, Cytogenetics, Neoplasms Diagnosis, Neoplasms Genetics, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Tissue (cell) Culture Genetic Disorders, Chromosome Abnormalities, Genetics, Genes, Gene Amplification, Genetics, Genes, Oncogenes, Genetics, Karyotypes, Genetics, Mutation, Chromosome Mutation, Deletion, Neoplasms Classification And Staging, Neoplasms Of Respiratory System, Oat Cell Carcinoma, Neoplastic Growth, Neoplasms Metastasis Histochemistry And Cytochemistry (general), Human, Tissues, Fluids Etc. From Non-related Sources Outside Immediate Project, Mammals, Rodents, Myomorpha, Athymic Mice (nude), Nucleic Acids, Dna Probe, Nucleic Acids, Synthetic Nucleic Acids, Hybrid Nucleic Acids, Immunochemistry 

  • Followup Grant: 5R01CA045745-02

[/dopaccordion]
[dopaccordion title=”Aisner, Joseph Specialized Center Support For A Cancer Research Center
Grant: 1P50CA032107-010004″ icon=27 activeicon=28]

Abstract: There is no text on file for this abstract. 

Tags: Drugs, Chemotherapy, Drugs Combination, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Of Respiratory System, Oat Cell Carcinoma, Neoplastic Therapy, Cancer Chemotherapy, Therapy Evaluation Antibiotics, Anthracyclines, Adriamycin, Antibiotics, Antineoplastic Antibiotics (general), Drugs Screening, Haloalkylamines, Cyclophosphamide, Immunology, Interferon, Metals, Heavy Metals, Platinum (compounds), Naphthalenes, Methylenedioxy-, Podophyllin, Neoplasms, Cancer Complications Of, Infections, Neoplastic Growth, Neoplasms Recurrence, Neoplastic Therapy, Cancer Radiotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Neoplastic Therapy, Palliative Treatment, Neoplastic Therapy, Thermotherapy, Radiography, Scanning, Cat, Respiratory Visualization, Lung Scanning, Sulfoxides, Dimethyl Sulfoxide Dosage And Route, Dosage, Human, Clinical

[/dopaccordion]
[dopaccordion title=”Aisner, Joseph Clinical Trials In Lung Cancers
Grant: 5P50CA032107-020004″ icon=27 activeicon=28]

Abstract: There is no text on file for this abstract. 

Tags: Drugs, Chemotherapy, Drugs Combination, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Of Respiratory System, Oat Cell Carcinoma, Neoplastic Therapy, Cancer Chemotherapy, Therapy Evaluation Antibiotics, Anthracyclines, Adriamycin, Antibiotics, Antineoplastic Antibiotics (general), Drugs Screening, Haloalkylamines, Cyclophosphamide, Immunity, Cytokines, Lymphokines, Interferon, Metals, Heavy Metals, Platinum (compounds), Naphthalenes, Methylenedioxy-, Podophyllin, Neoplasms, Cancer Complications Of, Infections, Neoplastic Growth, Neoplasms Recurrence, Neoplastic Therapy, Antineoplastic Agents, Neoplastic Therapy, Cancer Radiotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Neoplastic Therapy, Palliative Treatment, Neoplastic Therapy, Thermotherapy, Radiography, Scanning, Cat, Respiratory Visualization, Lung Scanning, Sulfoxides, Dimethyl Sulfoxide Dosage And Route, Dosage, Human, Clinical 

  • Followup Grant: 3P50CA032107-02S20004

[/dopaccordion]
[dopaccordion title=”Aisner, Joseph Cancer And Leukemia Group B
Grant: 2U10CA031983-12″ icon=27 activeicon=28]

Abstract: The UMCC has had continuing growth of its scientific and clinical relationships with CALGB. UMCC faculty participate in CALGB scientific and administrative committees. UMCC faculty design, conduct and chair many group studies and enter large numbers of patients (pts) onto CALGB studies. There has been greater than 40% growth in our accrual over the last 4 years. UMCC faculty sit on the core committees and chair the Acute Leukemia. UMCC sponsors the MCD CCOP, the Baltimore VA Medical Center (BVAMC), participating local physicians and the Vince Lombardi Cancer Center (VLCC). Funding to continue these activities will allow further growth in the scientific and administrative participation of UMCC and its affiliates in the group. UMCC phase I studies (2 – 4 per year) frequently evolve into group phase II studies. UMCC pilot studies (often performed with other CALGB institutions) have formed the conceptual basis for groupwide studies in leukemia, breast cancer and lung cancer. UMCC is one of the largest accruing institutions for leukemia and one of the largest accruing institutions overall. Our basic science laboratories studying acute leukemia, cellular, animal and clinical pharmacology, and cellular and molecular biology as well as the basic science laboratories of the VLCC, form an important correlative science resource for the group. UMCC and its collaborating institutions (BVAMC, MCD, participating physicians, and VLCC) propose to further our accrual beyond 300 entries per year onto CALGB studies. Participation in CALGB studies will allow UMCC and its affiliated physicians greater treatment options for patients with diseases under study by the group. The recent addition of three surgeons from UMCC to CALGB will further increment the main member institutional accrual. Ancillary studies in UMCC and VLCC laboratories in leukemia, small cell lung cancer, breast cancer and lymphoma will be of particular importance for correlative science. This grant will allow UMCC to continue its highly effective scientific and administrative participation in the group and will continue to allow us to develop a scientific base in the greater Baltimore/Washington area. This grant will also allow for the continuation of meritorious pilot protocols and will allow UMCC to monitor and collect data which will produce mutual benefit to the UMCC and CALGB. 

Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Hodgkin’s Disease, T Cell Receptor, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Acute Nonlymphocytic Leukemia, Adenocarcinoma, Asparaginase, Autologous Transplantation, Azacitidine, Bone Marrow Transplantation, Breast Neoplasm, Cachexia, Chlorambucil, Chromosome Translocation, Chronic Myelogenous Leukemia, Cis Platinum Compound, Clinical Study /trial, Colon Neoplasm, Colony Stimulating Factor, Cooperative Study, Cytosine Arabinoside, Deoxycoformycin, Diaziquone, Doxorubicin, Emotional Adjustment, Etoposide, Fluorouracil, Gene Expression, Gene Rearrangement, Hairy T Cell Leukemia, Hepatoma, Human Therapy Evaluation, Hydroxyurea, Immunoglobulin Gene, Interferon Alpha, Interferon Gamma, Interleukin 2, Leucovorin, Leukemia, Lung Neoplasm, Lymph Node Neoplasm, Lymphoma, Mesothelioma, Metastasis, Mitomycin C, Neoplasm /cancer Diagnosis, Neoplasm /cancer Genetics, Neoplasm /cancer Relapse /recurrence, Neoplasm /cancer Remission /regression, Nonhodgkin’s Lymphoma, Placebo, Postmenopause, Prednisone, Protooncogene, Quality Of Life, Rectum Neoplasm, Small Cell Carcinoma Of Lung, Social Adjustment, Splenectomy, Tamoxifen, Taxol, Trimetrexate, Tumor Antigen, Vincristine, Warfarin, Zidovudine Human Subject 

  • Followup Grant: 5U10CA031983-13
  • Followup Grant: 5U10CA031983-16

[/dopaccordion]
[dopaccordion title=”Dropulic, Boro Lentiviral Engineered T Cell Immunotherapy In Tumors Overexpressing Mesothelin
Grant: 1R43CA124273-01″ icon=27 activeicon=28]

Abstract: DESCRIPTION (provided by applicant): Project Summary/Abstract: The overall goal of this proposal is to evaluate the novel concept whether using lentiviral-engineered T cells that express chimeric receptors and signaling modules will improve efficacy for cancer immunotherapy directed against mesothelin. Mesothelin is a tumor associated antigen and a promising target in mesothelioma, ovarian, squamous cell cancers of head and neck, cervical, esophageal, pancreatic and many non-small cell lung cancers (NSCLC). In this proposal, we will test the fundamental hypothesis that human T cells with redirected specificity for carcinomas that express mesothelin can be created and can offer a clinically relevant and successful therapeutic approach. The ultimate goal is the development of a novel and improved therapy in those tumors for which the current therapies do not offer satisfactory results. Lentiviral vectors (LVs) have been successfully evaluated in Phase I clinical trials in patients with HIV/AIDS, offering the possibility to apply this technology for the treatment of cancer. Lentigen’s collaborator Dr. Carl June has helped pioneer adoptive immunotherapy as a potential therapeutic approach for hematologic malignancies. He has recently found that optimal growth of human CD8 cells required signals from CD137 (4-1BB). Therefore, in Aim 1 of this proposal, we will develop self inactivating (SIN) LVs expressing the chimeric anti-mesothelin single chain antibody, linked to the intracellular domain of the T cell receptor (TCR) zeta chain in tandem with 4-1BB (CD137) or CD28 intracellular co-stimulatory domains using a CD8 alpha hinge and trans-membrane domain. In Aim 2, we will test the anti-mesothelin LV vectors in T cells for safety and functionality. In Aim 3 in collaboration with Drs. June and Grupp, we will determine whether vector constructs are optimal to kill tumorigenic cells in vivo and to enable efficient engraftment and proliferation. In summary, Lentigen Corp., and Dr. June’s laboratory are uniquely positioned to provide the first comprehensive evaluation of the redirected T cell approach to generate anti-tumor effects in cancer patients and to apply this in a future clinical trial for patients with common and life threatening malignancies. Project Narrative: The ultimate goal of this proposal is the development of a novel and improved therapy for those tumors for which the current therapies do not offer satisfactory results. This therapy is based on activation of immune cells that will be manipulated in the laboratory and put back to the patient to fight cancer cells. Because of its great potential to offer a solution for those patients failing other therapies, this therapy will have a significant relevance for cancer patients and health care providers in the United States and worldwide. 

Tags: Immunotherapy, Neoplasm /cancer

[/dopaccordion]
[dopaccordion title=”Gabrielson, Edward W. Targeting Fatty Acid Synthase For Lung Cancer Treatment
Grant: 2P50CA058184-090017″ icon=27 activeicon=28]

Abstract: DESCRIPTION (provided by applicant): This project will target the enzyme, fatty acid synthase (FAS), for the treatment of lung cancer. Our preliminary studies have found that the vast majority of non-small cell lung cancers express high levels of this enzyme compared to normal tissues. This increased expression of FAS is significant because inhibition of this enzyme in cancer cells leads to a metabolic imbalance and cellular apoptosis. In a series of in vivo experiments, we found that treatment of orthotopic xenografts of human mesothelioma cells with an agent that inhibits FAS essentially abolished the growth of established tumors. Furthermore, in preliminary experiments, we found a promising anti-tumoral response of lung cancer orthotopic xenografts (in nude rats) treated with an FAS inhibitory compound. Importantly, these treatments did not result in any recognizable damage to normal tissue but did lead to dose-limiting anorexia. The proposed studies will further develop the use of FAS inhibitory therapy for lung cancer treatment. In the first phase of our preclinical studies, we will compare several novel FAS inhibitory agents, using in vivo and in vivo experimental systems, to identify a lead compound with high level of activity against lung cancer cells and tolerable levels of toxicity/anorexia. In the second phase of the preclinical studies, we will optimize dosing protocols for the treatment of lung cancer orthotopic xenografts using this compound. This optimization of treatment protocols could be useful for designing treatment protocols to be applied in the clinical setting. The third pre-clinical aim of this project is to examine the effects of the FAS inhibitory compound when used in combination with other agents, such as those currently used to treat lung cancer or being evaluated for treatment of lung cancer. Because the FAS target represents a pathway distinct from those targeted by other compounds, there is a significant potential that such combinations could have synergistic antineoplastic activity, thus allowing reduction of doses of the respective agents. The final aim of this project is to initiate a phase I clinical trial for a compound identified by the preclinical studies to have the best potential for lung cancer treatment. Successful completion of this phase I trial and the preclinical modeling studies will provide a framework for further evaluation of an FAS inhibitory compound in the treatment of lung cancer. 

Tags: Butyrolactone, Enzyme Inhibitor, Fatty Acid Synthase, Lung Neoplasm, Molecular Oncology, Neoplasm /cancer Chemotherapy Apoptosis, Cancer Prevention, Clinical Trial Phase I, Combination Chemotherapy, Disease /disorder Model, Drug Interaction, Enzyme Activity, Human Therapy Evaluation, Neoplasm /cancer Diagnosis Cell Line, Heterologous Transplantation, Human Subject, Human Tissue, Laboratory Rat, Patient Oriented Research, Positron Emission Tomography

[/dopaccordion]
[dopaccordion title=”Gabrielson, Edward W. Molecular Biology Of Mesothelioma Autocrine Growth Factors
Grant: 2S07RR005378-290925″ icon=27 activeicon=28]

Abstract: There is no text on file for this abstract. 

Tags: There Are No Thesaurus Terms On File For This Project.

[/dopaccordion]
[dopaccordion title=”Keogh, James P. Caret–the Baltimore Study Center
Grant: 2U01CA048196-06″ icon=27 activeicon=28]

Abstract: CARET is an ongoing double-blind lung cancer chemoprevention trial of the efficacy and safety of the combination of 30 mg beta-carotene and 25,000 IU retinyl palmitate daily in two high-risk populations: (a) male and female current and former smokers recruited primarily from insurance-based sources, and (b) males with extensive occupational asbestos exposure recruited primarily from employment-based sources. We have documented successful recruitment, excellent compliance, and minimal side effects, in over 15,000 participants randomized thus far at six study Centers. Through 30 April, 1993, CARET has randomized 4,000 asbestos-exposed workers, exceeding accrual goals at all five CARD asbestos centers, and 11,105 heavy smokers. Seattle and Portland have exceeded their heavy smoker goals, and Irvine is on track to achieve its goal in July 1994. During the final five-year period, CARET will focus on retention, adherence to protocol, ascertainment of endpoints, monitoring of key design parameters, closeout of the trial, and analysis and publication. Projections indicate that with 14,240 smokers and 4,010 asbestos-exposed participants and 114,100 person-years of follow-up through February 1998, CARET will be capable of detecting a 23% reduction in lung cancer incidence in the two high-risk populations combined, and 27%, 49%, 32%, and 35% reductions in the smokers, female smokers, male smokers, and asbestos-exposed subgroups, respectively. The University of Maryland Occupational Health Project received funding to initiate a Baltimore Study Center as part of CARET in October 1988. Recruitment and randomization of 808 asbestos-exposed participants was completed in February 1992; up to 20 participant spouses who themselves meet the criteria for heavy smokers are being recruited in year 5. During the final five year period the Baltimore Study Center will maintain the current high rates of study vitamin adherence and active participation. Staff will focus on retention and ascertainment and confirmation of primary and secondary endpoints. Specific preparations for study closeout and for analysis of data and dissemination of results will occur during the last two years. 

Tags: All Trans Retinol, Cancer Risk, Carotene, Chemoprevention, Lung Neoplasm, Nutrition Aspect Of Cancer, Vitamin Therapy Asbestos, Chemical Carcinogenesis, Clinical Trial, Cooperative Study, Disease Proneness /risk, Environment Related Neoplasm /cancer, Human Mortality, Longitudinal Human Study, Mesothelioma, Neoplasm /cancer Diagnosis, Occupational Hazard, Tobacco Abuse Human Subject, Nutrition Related Tag 

  • Followup Grant: 5U01CA048196-07
  • Followup Grant: 5U01CA048196-08

[/dopaccordion]
[dopaccordion title=”Van Echo, David A. Chemotherapy Committee: Calgb
Grant: 2U10CA044691-03″ icon=27 activeicon=28]

Abstract: 1. To review all Group protocols and concept sheets involving chemotherapy and biologic response modifiers during their preparation. 2. To introduce a program of population pharmacokinetics to a Cooperative Group setting. 3. To introduce a program of biotherapy into CALGB. 4. To review toxicities encountered during the course of Group studies. 5. To introduce new drugs and new combinations of established drugs into Group studies: in Phase II studies, and then, if indicated, Phase III comparative trials. 6. To conduct disease protocols for tumors or diseases not covered by other CALGB committees, e.g. Intergroup studies and pharmacology companion protocols. 7. To provide research symposia at Group meetings. 

Tags: Drugs, Pharmacology, Biochemical, Neoplasms Of Blood And Re System, Leukemia Acute, Neoplastic Therapy, Cancer Chemotherapy, Therapy Evaluation, Human Antibiotics, Anthracyclines, Adriamycin, Antibiotics, Bleomycin, Antineoplastic Agents, Antineoplastic Agents, Biological Response Modifiers, Drugs Adverse Effects, Drugs, Chemotherapy, Drugs Combination, Folic Acid Antagonists, Methotrexate, Metals, Heavy Metals, Platinum (compounds), Cis Platinum Compounds, Neoplasms Immunology, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Body Regions, Head And Neck, Neoplasms Of Reproductive System Male, Testis Neoplasms, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Of Reproductive System, Germ Cell Neoplasms, Pyrimidine Nucleosides, Cytosine Nucleosides, Cytosine Arabinoside, Cooperative Study Human, Clinical, Models, Mathematical

[/dopaccordion]
[dopaccordion title=”Van Echo, David A. Chemotherapy Committee: Cancer And Leukemia Group B
Grant: 5U10CA044691-04″ icon=27 activeicon=28]

Abstract: 1. To review all Group protocols and concept sheets involving chemotherapy and biologic response modifiers during their preparation. 2. To introduce a program of population pharmacokinetics to a Cooperative Group setting. 3. To introduce a program of biotherapy into CALGB. 4. To review toxicities encountered during the course of Group studies. 5. To introduce new drugs and new combinations of established drugs into Group studies: in Phase II studies, and then, if indicated, Phase III comparative trials. 6. To conduct disease protocols for tumors or diseases not covered by other CALGB committees, e.g. Intergroup studies and pharmacology companion protocols. 7. To provide research symposia at Group meetings. 

Tags: Drugs, Pharmacology, Biochemical, Neoplasms Of Blood And Re System, Leukemia Acute, Neoplastic Therapy, Cancer Chemotherapy, Therapy Evaluation, Human Antibiotics, Anthracyclines, Adriamycin, Antibiotics, Bleomycin, Antineoplastic Agents, Antineoplastic Agents, Biological Response Modifiers, Drugs Adverse Effects, Drugs, Chemotherapy, Drugs Combination, Folic Acid Antagonists, Methotrexate, Metals, Heavy Metals, Platinum (compounds), Cis Platinum Compounds, Neoplasms Immunology, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Body Regions, Head And Neck, Neoplasms Of Reproductive System Male, Testis Neoplasms, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Of Reproductive System, Germ Cell Neoplasms, Pyrimidine Nucleosides, Cytosine Nucleosides, Cytosine Arabinoside, Cooperative Study Human, Clinical, Models, Mathematical

[/dopaccordion]
[/dopaccordions]

Clinical Trials

[dopaccordions]
[dopaccordion title=”Active, not recruiting Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gefitinib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Capecitabine in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: doxorubicin hydrochloride;   Drug: ranpirnase
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
More Information

[/dopaccordion]
[dopaccordion title=”Completed Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura” icon=27 activeicon=28]

Condition: Esophageal Cancer;   Lung Cancer;   Malignant Mesothelioma;   Metastatic Cancer
Intervention: Drug: decitabine
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Decitabine and FR901228 in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases” icon=27 activeicon=28]

Condition: Esophageal Cancer;   Lung Cancer;   Malignant Mesothelioma;   Metastatic Cancer
Intervention: Drug: celecoxib;   Drug: decitabine;   Drug: romidepsin
More Information

[/dopaccordion]
[dopaccordion title=”Completed A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer” icon=27 activeicon=28]

Condition: Pancreatic Cancer;   Mesothelioma;   Ovarian Cancer;   Non-Small Cell Lung Cancer
Intervention: Drug: MORAb-009
More Information

[/dopaccordion]
[dopaccordion title=”Terminated Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment” icon=27 activeicon=28]

Condition: Malignant Epithelial Mesothelioma;   Adenocarcinoma of the Pancreas;   Carcinoma, Non-Small-Cell Lung;   Adenocarcinoma of the Ovaries
Intervention: Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer” icon=27 activeicon=28]

Condition: Esophageal Cancer;   Lung Cancer;   Malignant Mesothelioma;   Metastatic Cancer
Intervention: Drug: alvocidib;   Drug: romidepsin
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin;   Drug: cisplatin;   Drug: pemetrexed disodium;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Procedure: quality-of-life assessment
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma” icon=27 activeicon=28]

Condition: Mesothelioma
Intervention: Drug: MORAb-009;   Drug: Premetrexed;   Drug: Cisplatin
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Sorafenib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: sorafenib tosylate
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Mediastinal or Chest Wall Neoplasms, or Lung Metastases From Cancers of Non-Thoracic Origin” icon=27 activeicon=28]

Condition: Esophageal Cancer;   Lung Cancer;   Malignant Mesothelioma;   Metastatic Cancer
Intervention: Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Procedure: bronchoscopy;   Procedure: endoscopic biopsy;   Procedure: needle biopsy
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Mesothelioma;   Lung Cancer
Intervention: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683);   Drug: Comparator: Placebo
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

[/dopaccordion]
[dopaccordion title=”Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Pleural Neoplasms
Intervention: Drug: pemetrexed;   Drug: cisplatin
More Information

[/dopaccordion]
[dopaccordion title=”Completed Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors” icon=27 activeicon=28]

Condition: Cervical Cancer;   Fallopian Tube Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Ovarian Cancer;   Pancreatic Cancer;   Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
More Information

[/dopaccordion]
[/dopaccordions]
[/doptab]
[doptab title=”Doctors and Hospital”]

Hospital and Cancer Centers

Greenbaum Cancer Center 
22 S. Greene St.
Baltimore, MD
410.328.2703 

National Cancer Center
10 Center Dr Bldg. 10 Room 2-B07
Bethesda, MD
301.496.2195

Physicians

Richard Alexander, M.D.
University of Maryland Greenbaum Cancer Center
22 S. Greene St.
Baltimore, MD 21201
Telephone: 1-800-492-5538 or (410) 328-3828

Raffit Hassan, M.D.
National Cancer Institute
Building 37, Room 5116
Bethesda, MD 20892
(301) 451-8742

Stephen C. Yang, M.D., F.A.C.S, F.C.C.P. 
Chief, Division of Thoracic Surgery / Associate Professor of Surgery and Oncology 
The Johns Hopkins Hospital 
600 North Wolfe St. 
Baltimore, MD 21287 
(410) 614-3891

[/doptab]
[doptab title=”Cases”]

Philip Morris USA, Inc. v. Christensen
No. 68, September Term, 2005 , COURT OF APPEALS OF MARYLAND, August 4, 2006, Filed

Georgia-Pacific Corp. v. Benjamin
No. 52, September Term, 2005 , COURT OF APPEALS OF MARYLAND, August 2, 2006, Filed

Owens-Illinois, Inc. v. Cook
No. 10, September Term, 2003 , COURT OF APPEALS OF MARYLAND, April 26, 2005, Filed

Wilson v. John Crane, Inc.
No. 79, September Term, 2004 , COURT OF APPEALS OF MARYLAND, February 10, 2005, Filed

Rourke v. Amchem Prods., Inc.
No. 130, September Term, 2003 , COURT OF APPEALS OF MARYLAND , December 14, 2004, Filed

Atty. Griev. Comm’n v. Potter
No. 92, September Term, 2002 , COURT OF APPEALS OF MARYLAND, March 9, 2004, Filed

John Crane, Inc. v. Scribner
No. 92, No. 99, September Term, 2001, COURT OF APPEALS OF MARYLAND, June 11, 2002, Filed

Georgia-Pacific Corp. v. Pransky
No. 107, September Term, 2001, COURT OF APPEALS OF MARYLAND, June 11, 2002, Filed

Philip Morris, Inc. v. Angeletti
Misc. No. 2 September Term, 1998, COURT OF APPEALS OF MARYLAND, May 16, 2000, Filed

Pittsburgh Corning Corp. v. James
No. 136, Sept. Term, 1998, COURT OF APPEALS OF MARYLAND, April 23, 1999, Filed

[/doptab]
[doptab title=”Lawyers”]

Lawyers

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

[contact-form-7 id=”372″ title=”Occupation”]
[/doptab]
[/doptabs]

Get your free copy of
Surviving Mesothelioma Today!